Content often ends up at the bottom of the to-do list in most biotech and life science companies. But what if content was treated as a core pipeline-generation channel rather than an occasional marketing activity?
There’s a compelling case for doing exactly that.
According to the SciLeads 2026 Science Sales & Marketing Benchmarks, 29% of respondents identified inbound content as their largest source of pipeline. They put it ahead of outbound prospecting (23%), events (21%) and account-based campaigns (14%).
The research covered companies selling scientific equipment, instrumentation, consumables and reagents, as well as CROs, biotech and pharma businesses selling into biotech, academic and biopharma markets.
These are highly specialised markets, where finding qualified leads and converting them into customers remain two of the biggest commercial challenges. Which means the opportunity for content marketing is difficult to ignore.
What makes inbound content particularly valuable in biotech and life sciences?
Biotech and life science products are highly technical, and there is often a lot of detail to communicate before someone can make an informed decision.
Traditionally, much of that education happened after the first sales or business development meeting. A salesperson, BD manager, or investor relations representative could respond to specific questions, share technical information, address concerns, and provide the evidence needed to move a conversation forward.
But the way people research and evaluate companies has changed. More of that work now happens online, independently, before a potential customer, partner, or investor ever speaks to someone at the company.
That means companies can no longer rely on face-to-face conversations to do all the explaining. They need to make their expertise, technical information, and supporting evidence accessible much earlier in the decision-making process.
So why is this particularly important in biotech and life sciences? Two factors stand out:
1. Scientists are researchers by nature
Scientists are highly specialised, technically sophisticated, and often sceptical of traditional marketing claims. They want evidence, technical detail, and a clear understanding of how a product or service fits into their work. In a business-to-business (B2B) ecosystem, this discovery and buying process is rarely straightforward.
2. The buying journey happens in the dark
According to research by 6sense, B2B buyers complete roughly 60% to 70% of their buying journey digitally and independently before ever contacting a sales representative. Furthermore, this independent journey is getting longer every year, not shorter.
If potential customers, partners, or investors are spending most of their research time independently, the information they find online will dictate which companies make their shortlist.
That creates an invisibility problem for companies with limited content, outdated websites, or little technical information available online. They may have excellent products and expertise, but if that expertise isn't visible, potential customers may never discover it. Content helps put that expertise right in front of the market. It builds familiarity, demonstrates technical credibility, and gives potential buyers the data they need to evaluate a solution before a sales conversation even begins.
What should companies expect from investing in content marketing?
1. Inbound Lead Contribution: Around 30-35% of Total Leads
According to industry statistics compiled by InsightMark Research, inbound marketing accounts for approximately 34% of leads generated by businesses. The research also reports that inbound approaches generate 54% more leads than traditional outbound methods.
Inbound marketing encompasses a range of channels and formats, including blog content, search engine optimization (SEO), social media publishing, email newsletters, webinars and podcasts. These activities attract potential customers through organic discovery and engagement, rather than relying on direct outreach.
The economics are compelling, too. Inbound leads reportedly cost 62% less to generate than outbound leads, while content marketing generates three times more leads than paid search.
2. Strategic Partnerships: Activating the 95% of Unreachable Prospects
Data from the Edelman & LinkedIn B2B Thought Leadership Impact Report indicates that 95% of business clients are not actively shopping for new solutions at any given moment, making traditional outbound pitches ineffective. However, 75% of executives report that strong technical content has directly prompted them to investigate an organization's capabilities and explore options they were not previously considering.
In highly regulated, highly technical fields like biotech and pharma, this passive influence trends significantly higher. Because big pharma scouting teams and corporate development executives are deeply risk-averse, they can spend months quietly auditing a biotech’s public-facing data, publications, and technical frameworks in the "dark funnel" before ever opening lines of formal communication.
High-quality content effectively acts as your inbound business development engine, and this approach can heavily influence how partners perceive you. According to the Edelman & LinkedIn B2B Thought Leadership Impact Report, 86% of surveyed decision-makers state it has prompted them to invite a company to bid for a contract, and 90% report they are more open to sales and marketing outreach from companies that consistently publish valuable insights
3. Investor Relations: Making Complex Science Accessible to Investors
Most biotech investors, particularly retail investors, do not have a science background. They may understand financial markets but not necessarily the biology, clinical data or regulatory pathways behind a company's technology. That's where good content comes in: making complex science easier to understand, explaining why it matters commercially and, importantly, what makes the technology different from competitors.
Digital channels are also an important part of how institutional investors research companies. Global research by Coalition Greenwich and LinkedIn found that 48% of institutional investors use LinkedIn as a source of investment-related information and information they encountered on social media prompted them to conduct further independent research on an industry issue or topic. Institutional investors were also 4x more likely to use LinkedIn than other social platforms for in-depth subject matter education.
Retail investor research habits show a similar shift. A March 2026 survey of nearly 7,200 US retail investors found that 56% use YouTube for investment research, while 52–63% of investors aged 22–37 had purchased shares based on social media content.
For biotech companies, this means investor communication needs to go beyond publishing market announcements. Technical explainers, data visualizations, expert commentary and regular updates can help investors understand the science, recognize competitive advantages and follow the commercial opportunity between major milestones.
It's time to treat content as a commercial asset
The companies getting ahead are investing in content strategies that understand their audiences, communicate what matters to them, and give them a reason to pay attention, engage and start a conversation. This is reflected in the SciLeads 2026 Science Sales & Marketing Benchmarks, which found that inbound content ranked ahead of outbound prospecting, events and account-based campaigns as a source of pipeline among surveyed science-focused companies.
For companies looking to generate more qualified pipeline, attract strategic partners, and build investor confidence, content deserves a more deliberate investment.
